# 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

> **NCT03468335** · PHASE3 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 151 (actual)

## Conditions studied

- Locally Advanced Pancreatic Cancer
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan Liposomal Injection [Onivyde]

## Key facts

- **NCT ID:** NCT03468335
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-31
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2025-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468335, "2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03468335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*